BSX Relative Valuation
BSX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, BSX is overvalued; if below, it's undervalued.
Historical Valuation
Boston Scientific Corp (BSX) is now in the Overvalued zone, suggesting that its current forward PE ratio of 35.98 is considered Overvalued compared with the five-year average of 26.58. The fair price of Boston Scientific Corp (BSX) is between 73.67 to 92.73 according to relative valuation methord. Compared to the current price of 104.50 USD , Boston Scientific Corp is Overvalued By 12.70%.
Relative Value
Fair Zone
73.67-92.73
Current Price：104.50
12.70%
Overvalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
7.06
P/B
Median3y
4.79
Median5y
4.32
1.92
FCF Yield
Median3y
1.55
Median5y
1.83
Competitors Valuation Multiple
The average P/S ratio for BSX's competitors is 7.74, providing a benchmark for relative valuation. Boston Scientific Corp Corp (BSX) exhibits a P/S ratio of 7.83, which is 1.18% above the industry average. Given its robust revenue growth of 20.93%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Boston Scientific Corp (BSX) currently overvalued or undervalued?
What is Boston Scientific Corp (BSX) fair value?
How does BSX's valuation metrics compare to the industry average?
What is the current P/B ratio for Boston Scientific Corp (BSX) as of May 24 2025?
What is the current FCF Yield for Boston Scientific Corp (BSX) as of May 24 2025?
What is the current Forward P/E ratio for Boston Scientific Corp (BSX) as of May 24 2025?